| To: kendall harmon who wrote (410) | 4/27/2002 10:37:01 AM | | From: Bruce A. Brotnov | | | | Kendall, yes I saw it in 4/25 IBD and was thinking I should be holding some more BLUD but at least I had some at the time. I seriously considered putting it in Poorman's Model Portfolio the day before, but held off for some reason.
I also like AIRM for the long haul. As I have been screening earnings all week it seems like the medical sector continues to have a very strong representation among growth stocks and home builders look to be slowing down from their torrid growth. PEs are even starting to get over 10 now so they will probably see dumping down the road.
Bruce |
| | Immucor | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Thomas Kirwin who wrote (398) | 7/17/2002 10:52:07 AM | | From: Ron | | | | Immucor Earns Record $2.8 Million in Net Income for the Fiscal Fourth Quarter
Record Revenues, Gross Profits and Net Income
NORCROSS, Ga., Jul 17, 2002 /PRNewswire-FirstCall from COMTEX/ -- Immucor, Inc. (Nasdaq: BLUD chart, msgs), the global
leader in providing automated instrument-reagent systems to the blood transfusion industry, today reported financial results for the
fiscal fourth quarter and twelve months ended May 31, 2002, and updated its guidance for fiscal 2003.
Revenue for the fiscal fourth quarter ended May 31, 2002 was a record $23.5 million, up 25.6% from $18.7 million in the same
period last year. Income before income taxes reached $4.4 million versus a net loss before income taxes of $(0.3) million in the
year ago period. Net income for the fourth quarter was $2.8 million versus a net loss of $(1.4) million for the same quarter last year.
Diluted earnings per share were $0.34 on 8.2 million weighted average shares outstanding compared with $(0.19) on 7.3 million
weighted average shares outstanding for the same period last year. Earnings before interest, taxes, depreciation and amortization
(EBITDA) improved, reaching $7.0 million for the quarter versus $2.3 million in the same period last year.
Reagent revenues grew to $20.6 million compared to $17.6 million in the fourth quarter 2001, a 17.0% increase. The Company
believes growth in reagent revenue occurred as a result of new customers, price increases in North America and volume increases
in proprietary Capture(R) products. Reagent gross margins grew to 58% during the quarter. Sales of instruments during the quarter
were particularly strong at $2.8 million vs. $1.1 million in the previous year. Instrument sales grew as a result of new placements
and concentrated efforts to reduce the backlog of instruments installed but not recorded as revenue due to post installation criteria.
The instrument backlog currently stands at $0.7 million. During the third quarter the Company fully utilized net operating loss
carry-forwards generated in fiscal 2001 and, as a result, the Company's U.S. operations have become fully taxed during the fourth
quarter. |
| | Immucor | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: Bruce A. Brotnov who wrote (411) | 8/8/2002 9:31:00 PM | | From: Ron | | | | Immucor CEO Comments On Stock Activity
DOW JONES NEWSWIRES
NORCROSS, Ga. -- Immucor Inc.'s (BLUD) chief executive, Edward L. Gallup, said the company isn't aware of any reason why its stock price was down more than 11% in heavy trading Thursday. In a press release, Gallup said the company hasn't changed its recent guidance for the current quarter or for 2003.
In July, Immucor said it expected 2003 earnings of $13 million to $13.5 million, or $1.32 to $1.38 a share, on
revenue of $94 million to $96 million. In fiscal 2002, the company earned $8.8 million, or $1.15 a diluted share, on sales of $84.1 million.
For the first quarter, Immucor expects to earn 27 cents to 29 cents a share, compared to 17 cents a year earlier. Shares of Immucor recently traded at $23.20, down $2.92, or 11.2%, on Nasdaq market composite volume of 854,700 shares. Average daily volume is 246,670 shares.
-Kara Wetzel, Dow Jones Newswires, 201-938-5388.
As reported Wednesday, three Immucor executives, including Chief Financial Officer Steven Ramsey, sold company stock in July.
Ramsey exercised options for 24,570 shares and sold the stock from July 19 to July 31. He told Dow Jones
Newswires he needed the cash for a real estate investment. He held 5,000 shares at the end of the month with options to acquire 20,570 more. Two other officers sold a total of 17,000 shares in July.
Shares of Immucor continued to trade heavily Thursday, recently changing hands at $23.25, down $2.87, or 11%, on volume of 1.0 million shares. |
| | Immucor | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Bruce A. Brotnov who wrote (415) | 8/12/2002 10:58:10 AM | | From: Ron | | | | NORCROSS, Ga., Aug. 12 / Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated
instrument-reagent systems to the blood transfusion industry, refuted today an August 8, 2002 research report by Sterling Research, a division of Sterling Financial Investment Group. Edward L. Gallup, President and Chief Executive Officer of Immucor, said, "This is a very serious misunderstanding of the facts. Immucor believes
Sterling's August 8 research report is based almost entirely on serious factual inaccuracies concerning Olympus, an instrument manufacturer that uses Immucor's FDA-licensed reagents on its PK7200 automated blood donor
instrument. The Sterling report concludes that a significant amount of Immucor's revenues are exposed to potential erosion because Olympus controls a major portion of the North American blood-testing market and is getting ready
to sell its own reagents in competition with Immucor. In fact, Olympus operates in an important but relatively small part of Immucor's overall blood- testing market, and the FDA-licensed reagents Olympus intends to use on its
instrument have been developed and manufactured by Immucor's wholly-owned subsidiary, Gamma Biologicals, Inc." Mr. Gallup added, "Reagent sales for the Olympus instrument are not material to Immucor's operations."
Immucor has demanded that Sterling immediately correct all inaccuracies in the report.
Founded in 1982, Immucor manufactures and sells a complete line of
reagents and systems used by hospitals, reference laboratories and donor
centers to detect and identify certain properties of the cell and serum
components of blood prior to transfusion. Immucor markets a complete family
of automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website at
www.immucor.com . |
| | Immucor | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: NOW who wrote (418) | 10/23/2002 5:45:36 PM | | From: Bruce A. Brotnov | | | | Yes, I trimmed some too soon to buy RMCI too soon, but still have some BLUD and glad I didn't sell it all. Not sure how long it can continue to hit new highs, but still going. It was put in Poormans model portfolio (at least one that worked - LOL ) at split adjusted 13.33 on 8/9.
I am looking to trim it pretty soon.
Bruce
www.poormans.com |
| | Immucor | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: NOW who wrote (418) | 4/10/2003 10:54:35 AM | | From: Ron | | | | from the 8-K: The Company expects revenues for the fiscal year ended May 31, 2004 to range from $106 million to $109 million, an increase of approximately 11% to 12% over 2003 revenues. Net income is expected to be in the range of $17.1 to $19.1 million, an approximate 25% to 33% increase over fiscal 2003. We expect to generate record earnings per share (fully diluted) in the range of $1.20 to $1.34 for the full fiscal year. We base our projections on our history of operations and experience, the recurring nature of our revenues, including contractually committed purchases from large customers, and the predictability of our expenses through the fiscal year. In making this projection, management has made the following assumptions:
With respect to revenues, the Company has extrapolated recent past results and assumed the Company will generate additional revenues from the renewal of customer contracts at higher prices, the additional sales of instruments and the related reagent revenue in the United States, the sales of the new Galileo instrument in Europe and the related reagent revenue, and from the increased sales of the Company’s diagnostic products. The Company has also assumed that the recently announced development agreement with Inamed, Inc. for the production of human collagen mesh will result in the successful development of a product that would add revenues beginning no later than February 2004. Assuming that occurs, the Company expects annual revenues ranging between $6.0 million and $8.0 million dollars from the Inamed agreement and an addition to quarterly earnings of approximately $0.03 per diluted share outstanding when shipments commence.
With respect to expenses, the Company has assumed expenses will grow at a rate slightly higher than the rate of inflation.
With respect to fully-diluted earnings per share, the Company’s projection assumes no additional capital stock will be issued but believes the number of fully diluted shares will increase due to a higher share price since this affects assumptions required by accounting principles regarding unexercised stock options.
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments.
For more information on Immucor, please visit our website at www.immucor.com. |
| | Immucor | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
